AH

Apeiron Holdings Limited

North America, Massachusetts, United States, Boston

Description

Apeiron Holdings Limited is a private investment office founded to leverage investment opportunities of its affiliate Apeiron Partners.

Investor Profile

Apeiron Holdings Limited has made 2 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series A (100%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Life Science
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Apeiron Holdings Limited frequently co-invest with?

Gaingels
North America, Vermont, United States, Burlington
Co-Investments: 1
Dolby Family Ventures
North America, California, United States, San Francisco
Co-Investments: 1
Negev Capital
North America, Midland, Cayman Islands, Grand Cayman
Co-Investments: 1
Artis Ventures (AV)
North America, California, United States, San Francisco
Co-Investments: 1
Noetic Fund
North America, Ontario, Canada, Toronto
Co-Investments: 1
BC
North America, California, United States, Santa Monica
Co-Investments: 1
OMX Ventures
North America, Illinois, United States, Lincolnshire
Co-Investments: 1
PS
North America, Illinois, United States, Highland Park
Co-Investments: 1
Casa Verde Capital
North America, California, United States, Los Angeles
Co-Investments: 1
OP
North America, NA - Puerto Rico, Puerto Rico, San Juan
Co-Investments: 1

What are some of recent deals done by Apeiron Holdings Limited?

Delix Therapeutics

Boston, Massachusetts, United States

Delix Therapeutics focuses on harnessing the power of psychoplastogens novel neuroplasticity-promoting therapeutic.

BiotechnologyHealth CareLife Science
Series ASep 27, 2021
Amount Raised: $70,000,000
EnBiotix

Cambridge, Massachusetts, United States

EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.

BiotechnologyHealth CarePharmaceutical
Series AMay 12, 2016